J&J Zarnestra Receives “Not Approvable” Letter From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”